A direct diabetes comparison, reported by the sponsor
Lilly’s October 28, 2026 TRANSCEND-T2D-2 announcement reports a direct comparison of investigational retatrutide with injectable Ozempic 2 mg in adults with type 2 diabetes. It is sponsor topline, not a peer-reviewed primary paper.
That is different from a placebo-controlled retatrutide obesity trial and different from a comparison with Wegovy or oral semaglutide. The population, comparator and source type are essential parts of the result.
Keep the study identity attached to the numbers
| Detail | Reported study context |
|---|---|
| Participants | 1, 298 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor. |
| Design/time | Randomized, open-label phase 3; 80 weeks. |
| Study groups | Retatrutide 9 mg or 12 mg versus injectable Ozempic 2 mg. These are study methods, not reader dosing instructions. |
| Primary objective | A1C noninferiority for the 12 mg retatrutide regimen. |
| Analysis in release | Efficacy estimand, assuming continued intervention without specified additional glucose-lowering treatment. |
An estimand states the treatment-effect question an analysis is trying to answer. Here, the reported question differs from simply describing every randomized participant’s experience regardless of stopping or adding treatment. That distinction should stay beside the headline result.
The limited topline result
| Reported outcome | Retatrutide 9 mg | Retatrutide 12 mg | Ozempic 2 mg |
|---|---|---|---|
| Mean weight change | −19.5% | −20.9% | −9.4% |
| Mean A1C change | −2.2 percentage points | −2.2 percentage points | −1.8 percentage points |
| Discontinued treatment due to adverse events | 4.8% | 7.9% | 2.7% |
A1C changes are percentage points, not relative percent improvements. The release identifies gastrointestinal events as most common and qualifies the 9 mg A1C superiority comparison as nominal rather than one of the multiplicity-controlled claims. The release is an early summary rather than a full research report.
Why this is not a three-drug ranking
The comparator here was injectable Ozempic 2 mg. It was not Wegovy, oral Ozempic, every semaglutide regimen or tirzepatide. People with type 2 diabetes on the trial’s background therapy are also a different population from adults without diabetes in an obesity study.
TRIUMPH-1 supplies placebo-controlled obesity evidence for retatrutide; SURMOUNT-5 supplies a tirzepatide/semaglutide comparison in adults with obesity without diabetes. Placing all their percentages on one bar chart would hide those design differences rather than create a valid direct comparison.
Topline releases are useful early primary sponsor information, but a full paper, protocol and supplementary analyses can add detail about missing data, exposure, harms and interpretation. This article keeps the available result dated and attributed instead of presenting an awaited publication as already reviewed.
Trial findings do not confer approval
Retatrutide remained investigational at the source check. No approved consumer retatrutide product or launch date is established here. The Ozempic comparator has its own approved product information, including important safety warnings and indication limits; this trial report does not change those labels.
What should readers look for next?
The full peer-reviewed report and its supplement, with prespecified analysis details and a fuller safety description. For a headline comparison, also check whether the reported number is an efficacy estimand or another analysis and whether the comparator is the product you thought it was.
Does this answer a personal treatment choice?
A current treatment decision also requires an approved product, relevant indication, medical history and professional assessment. Research status and comparative trial evidence are useful to understand without becoming a self-directed switching plan.
Read next
Sources and method
- Lilly TRANSCEND-T2D-2 release, October 28, 2026 — pages 1–2 reviewed in the source audit. Sponsor topline, not a verified peer-reviewed primary paper; NCT06260722.
- Lilly: what to know about retatrutide — October 2026 status: investigational and not marketed.
- Ozempic injection prescribing information, May 2026 — sections 1, 3, 12.1 and Medication Guide.
- Jastreboff et al., TRIUMPH-1, NEJM, September 29, 2026 — primary abstract reviewed; DOI 10.1056/NEJMoa 2604169, NCT05929066. Full paper/appendix unavailable. Lilly funded.
- Aronne et al., SURMOUNT-5, NEJM 2025 — primary abstract reviewed; DOI 10.1056/NEJMoa 2416394. Full journal text/appendix unavailable in the sources reviewed. Lilly funded.
Sources checked October 29, 2026.
Prepared by GLP Finds with AI-assisted writing and checked against the listed sources. Our editorial process. This article has not received independent clinical review.